Dual anti-platelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the current gold standard for the treatment of acute coronary syndrome (ACS). Clopidogrel or ticagrelor are the preferred P2Y12 inhibitor options for initial therapy. Ticagrelor has been demonstrated to have improved efficacy, and is preferred over clopidogrel in the absence of contraindications or the need for oral anticoagulation.

The main risk associated with all antiplatelet therapies is bleeding, and physicians need to carefully weigh the possible adverse effects against the benefits of prescribing these drugs to patients with ACS. Aspirin continues to be prescribed almost ubiquitously for patients with ACS, and P2Y12 antagonists are now often added in; such dual antiplatelet therapy confers greater antithrombotic efficacy but at the risk of increased bleeding. Over recent years, it has become apparent that these drugs may also exert powerful anti-inflammatory effects that provide additional benefit in the management of ACS.

Related Articles


Type and Duration of Antithrombotic Treatment in Complex PCI

Despoina-Rafailia Benetou, Charalampos Varlamos, Christos Pappas,


Citation: US Cardiology Review 2021;15:e17.

APSC Consensus Recommendations on High-risk Chronic Coronary Syndrome

Jack Wei Chieh Tan, Derek P Chew, David Brieger,


Citation: European Cardiology Review 2021;16:e26.

Antithrombotic Therapy in Complex PCI Patients Under OAC

Despoina-Rafailia Benetou, Panayotis K Vlachakis, Charalampos Varlamos,


Citation: US Cardiology Review 2021;15:e09.

Pharmacotherapy in Stable CAD: The ISCHEMIA Trial

Jonathan Yap, Derek P Chew, Gregg Stone,


Citation: European Cardiology Review 2021;16:e04.